Search

Your search keyword '"Bektic, Jasmin"' showing total 532 results
Start Over Author "Bektic, Jasmin"
532 results on '"Bektic, Jasmin"'

2. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Author

Kafka, Mona, Horninger, Andreas, di Santo, Gianpaolo, Virgolini, Irene, Neuwirt, Hannes, Unterrainer, Lena M., Kunte, Sophie C., Deiss, Emil, Paffenholz, Pia, Heidenreich, Axel, Rasul, Sazan, Einspieler, Holger, Shariat, Shahrokh F., Rajwa, Pawel, Dozauer, Robert, Tsaur, Igor, Medlock, Ellen, Rölz, Niklas, Rausch, Steffen, la Fougère, Christian, Trautwein, Nils, Roesch, Marie C., Merseburger, Axel S., Zattoni, Fabio, Sepulcri, Matteo, Ladurner, Michael, Bektic, Jasmin, Gandaglia, Giorgio, Horninger, Wolfgang, and Heidegger, Isabel

Published
2024
Full Text
View/download PDF

3. Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study

Author

Kafka, Mona, Giannini, Giulia, Artamonova, Nastasiia, Neuwirt, Hannes, Ofner, Heidemarie, Kramer, Gero, Bauernhofer, Thomas, Luger, Ferdinand, Höfner, Thomas, Loidl, Wolfgang, Griessner, Hubert, Lusuardi, Lukas, Bergmaier, Antonia, Berger, Andreas, Winder, Thomas, Weiss, Sarah, Bauinger, Severin, Krause, Steffen, Drerup, Martin, Heinrich, Elmar, Schneider, Magdalena, Madersbacher, Stephan, Vallet, Sonia, Stoiber, Franz, Laimer, Sarah, Hruby, Stephan, Schachtner, Gert, Nagele, Udo, Lenart, Sebastian, Ponholzer, Anton, Pfuner, Jacob, Wiesinger, Clemens, Kamhuber, Christoph, Müldür, Ecan, Bektic, Jasmin, Horninger, Wolfgang, and Heidegger, Isabel

Published
2024
Full Text
View/download PDF

7. Efficacy and safety of rechallenge with [177Lu]Lu-PSMA-I&T radioligand therapy in metastatic castration resistant prostate cancer.

Author

Santo, Giulia, Di Santo, Gianpaolo, Sviridenko, Anna, Bayerschmidt, Steffen, Wirth, Lukas, Scherbauer, Fabian, Lehmann, Peter, von Guggenberg, Elisabeth, Decristoforo, Clemens, Heidegger-Pircher, Isabel, Bektic, Jasmin, and Virgolini, Irene

Subjects
CASTRATION-resistant prostate cancer, KIDNEY failure, OVERALL survival, POSITRON emission tomography, THROMBOCYTOPENIA, PREVENTIVE medicine
Abstract

Background: The purpose of this study was to evaluate the safety and outcome of rechallenge [177Lu]Lu-PSMA-I&T in newly progressed mCRPC patients after response to initial [177Lu]Lu-PSMA radioligand therapy (PRLT). Methods: We retrospectively included 18 patients who underwent rechallenge with [177Lu]Lu-PSMA-I&T. All patients presented with (i) newly progressed disease after response to initial PRLT; (ii) a [68Ga]Ga-PSMA-11 PET/CT confirming the presence of PSMA-positive metastases; iii) ECOG performance status 0–1. Adverse events were graded according to CTCAE v5.0. Response was assessed by PSA and classified according to PCWG3 recommendations. For patients who underwent restaging with [68Ga]Ga-PSMA-11 PET/CT, imaging response was categorised according to adapted PERCIST v1.0. In patients with discordant [68Ga]Ga-PSMA-11 PET/CT and PSA, other available imaging modalities were evaluated to confirm disease status. Overall survival (OS) was calculated from the first cycle of initial PRLT and rechallenge PRLT, respectively, until last patient contact or death. Results: Patients were initially treated with a median of 5 cycles (range 4–7) and were rechallenged after a median of 9 months (range 3–13). Each patient received a median of 4 (range 2–7) rechallenge cycles (median cumulative activity 26.1 GBq). None of the patients experienced life-threatening G4 adverse events during either treatment period. Grade 3 adverse events included one case of anaemia, one case of thrombocytopenia, and one case of renal failure. In 8/18 patients long-term toxicities were evaluated. Serious toxicities (≥ Grade 3) occurred in 3/8 patients (n = 1 G4 thrombocytopenia, n = 1 G4 renal failure and n = 1 pancytopenia and G4 renal failure). Best PSA50%-response was observed in 44% of patients and PSA-disease control was confirmed in 56% of patients at the last cycle. Of the 12/18 patients restaged by imaging, 6/12 (50%) patients had disease control (partial response/stable disease), 1/12 had a mixed response, and 5/12 had progression. After a median follow-up time of 25 months (range 14–44), 10 patients had died, 7 were still alive, and one patient was lost at follow-up. The median OS was 29 months (95%CI, 14.3–43.7 months) for the initial treatment and 11 months (95%CI, 8.1–13.8 months) for the first rechallenge course. Conclusion: More than half of patients benefit from rechallenge PRLT. Our analysis suggests that rechallenge may prolong survival in selected patients, with an acceptable safety profile. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

15. Real-world Outcomes and Predictive Biomarkers for 177Lutetium Prostate-specific Membrane Antigen Ligand Treatment in Metastatic Castration-resistant Prostate Cancer: A European Association of Urology Young Academic Urologists Prostate Cancer Working Group Multi-institutional Observational Study

Author

Kafka, Mona, primary, Horninger, Andreas, additional, di Santo, Gianpaolo, additional, Virgolini, Irene, additional, Neuwirt, Hannes, additional, Unterrainer, Lena M., additional, Kunte, Sophie C., additional, Deiss, Emil, additional, Paffenholz, Pia, additional, Heidenreich, Axel, additional, Rasul, Sazan, additional, Einspieler, Holger, additional, Shariat, Shahrokh F., additional, Rajwa, Pawel, additional, Dozauer, Robert, additional, Tsaur, Igor, additional, Medlock, Ellen, additional, Rölz, Niklas, additional, Rausch, Steffen, additional, la Fougère, Christian, additional, Trautwein, Nils, additional, Roesch, Marie C., additional, Merseburger, Axel S., additional, Zattoni, Fabio, additional, Sepulcri, Matteo, additional, Ladurner, Michael, additional, Bektic, Jasmin, additional, Gandaglia, Giorgio, additional, Horninger, Wolfgang, additional, and Heidegger, Isabel, additional

Published
2023
Full Text
View/download PDF

22. Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response

Author

Kafka, Mona, primary, Burtscher, Thomas, additional, Fritz, Josef, additional, Schmitz, Maximilian, additional, Bektic, Jasmin, additional, Ladurner, Michael, additional, Horninger, Wolfgang, additional, and Heidegger, Isabel, additional

Published
2022
Full Text
View/download PDF

29. Identification of functionally active, low frequency copy number variants at 15q21.3 and 12q21.31 associated with prostate cancer risk

Author

Demichelis, Francesca, Setlur, Sunita R., Banerjee, Samprit, Chakravarty, Dimple, Chen, Jin Yun Helen, Chen, Chen X., Huang, Julie, Beltran, Himisha, Oldridge, Derek A., Kitabayashi, Naoki, Stenzel, Birgit, Schaefer, Georg, Horninger, Wolfgang, Bektic, Jasmin, Chinnaiyan, Arul M., Goldenberg, Sagit, Siddiqui, Javed, Regan, Meredith M., Kearney, Michale, Soong, T. David, Rickman, David S., Elemento, Olivier, Wei, John T., Scherr, Douglas S., Sanda, Martin A., Bartsch, Georg, Lee, Charles, Klocker, Helmut, and Rubin, Mark A.

Published
2012

30. TURP bei hochbetagten Patienten (85 Jahre und älter): Eine retrospektive, multizentrische Untersuchung

Author

Lotterstätter, Michael, Seklehner, Stephan, Wimpissinger, Florian, Gombos, Jozsef, Ramesmayer, Christian, Bektic, Jasmin, Stolzlechner, Philipp, Laimer, Sarah, and Madersbacher, Stephan

Subjects
ddc: 610, Medicine and health
Abstract

Einleitung: Der demographische Wandel führt zu einer deutlichen Zunahme von betagten/hochbetagten Patienten, die eine minimal-invasive/chirurgische Intervention bei BPE/LUTS benötigen. Ziel dieser Studie war das Ergebnis von 85+ Patienten, die mittels TURP behandelt wurden, [zum vollständigen Text gelangen Sie über die oben angegebene URL]

Published
2022

39. A real-world comparison of docetaxel versus abiraterone acetate for metastatic hormone-sensitive prostate cancer

Author

Tsaur, Igor, Heidegger, Isabel, Bektic, Jasmin, Kafka, Mona, Van Den Bergh, Roderick C. N., Hunting, Jarmo C. B., Thomas, Anita, Brandt, Maximilian P., Höfner, Thomas, Debedde, Eliott, Thibault, Constance, Ermacora, Paola, Zattoni, Fabio, Foti, Silvia, Kretschmer, Alexander, Ploussard, Guillaume, Rodler, Severin, Amsberg, Gunhild Von, Tilki, Derya, Surcel, Christian, Rosenzweig, Barak, Gadot, Moran, Gandaglia, Giorgio, Dotzauer, Robert, Tsaur, I., Heidegger, I., Bektic, J., Kafka, M., van den Bergh, R. C. N., Hunting, J. C. B., Thomas, A., Brandt, M. P., Hofner, T., Debedde, E., Thibault, C., Ermacora, P., Zattoni, F., Foti, S., Kretschmer, A., Ploussard, G., Rodler, S., von Amsberg, G., Tilki, D., Surcel, C., Rosenzweig, B., Gadot, M., Gandaglia, G., and Dotzauer, R.

Subjects
Male, hormonal therapy, 610 Medizin, Abiraterone Acetate, Clinical Cancer Research, Androgen Antagonists, Docetaxel, Middle Aged, chemotherapy, prostate cancer, hormone‐sensitive, Progression-Free Survival, Prostatic Neoplasms, Castration-Resistant, 610 Medical sciences, Antineoplastic Combined Chemotherapy Protocols, Humans, hormone-sensitive, metastasis, Research Articles, Aged, Retrospective Studies, Research Article
Abstract

Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. Methods In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. Results Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p, Abiratreone acetate outperforms docetaxel in terms of PFS and PFS2, while the impact on OS as well as the rate of side effects is similar between both groups in real‐life utilization. Prospective randomized trials of available agents in mHSPC are required to generate high‐level evidence to facilitate sensible drug selection

Published
2021

40. Validation of Cell-Free RNA and Circulating Tumor Cells for Molecular Marker Analysis in Metastatic Prostate Cancer

Author

Ladurner, Michael, primary, Wieser, Manuel, additional, Eigentler, Andrea, additional, Seewald, Martin, additional, Dobler, Gabriele, additional, Neuwirt, Hannes, additional, Kafka, Mona, additional, Heidegger, Isabel, additional, Horninger, Wolfgang, additional, Bektic, Jasmin, additional, Klocker, Helmut, additional, Obrist, Peter, additional, and Eder, Iris E., additional

Published
2021
Full Text
View/download PDF

50. Dual Inhibitory Action of a Novel AKR1C3 Inhibitor on Both Full-Length AR and the Variant AR-V7 in Enzalutamide Resistant Metastatic Castration Resistant Prostate Cancer

Author

Kafka, Mona, primary, Mayr, Fabian, additional, Temml, Veronika, additional, Möller, Gabriele, additional, Adamski, Jerzy, additional, Höfer, Julia, additional, Schwaiger, Stefan, additional, Heidegger, Isabel, additional, Matuszczak, Barbara, additional, Schuster, Daniela, additional, Klocker, Helmut, additional, Bektic, Jasmin, additional, Stuppner, Hermann, additional, and Eder, Iris E., additional

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results